Li X, Li N, Pei H, Ren Y, Li L, Sun L
Front Cell Infect Microbiol. 2024; 14:1500111.
PMID: 39698319
PMC: 11652507.
DOI: 10.3389/fcimb.2024.1500111.
Wang M, Seibel M
Osteoporos Int. 2024; 35(8):1359-1376.
PMID: 38652313
PMC: 11281980.
DOI: 10.1007/s00198-024-07036-1.
Polyzou M, Kiefer D, Baraliakos X, Sewerin P
Front Med (Lausanne). 2023; 10:1167033.
PMID: 37200966
PMC: 10186618.
DOI: 10.3389/fmed.2023.1167033.
Beauvais C
Rev Rhum Ed Fr. 2022; 89(6):555-561.
PMID: 36267475
PMC: 9558089.
DOI: 10.1016/j.rhum.2022.09.013.
Beauvais C
Joint Bone Spine. 2022; 89(4):105371.
PMID: 35257865
PMC: 9548403.
DOI: 10.1016/j.jbspin.2022.105371.
Romosozumab, clinical trials, and real-world care of patients with osteoporosis.
Lewiecki E
Ann Transl Med. 2020; 8(15):974.
PMID: 32953774
PMC: 7475409.
DOI: 10.21037/atm.2020.03.196.
Expert quotes and exaggeration in health news: a retrospective quantitative content analysis.
Bossema F, Burger P, Bratton L, Challenger A, Adams R, Sumner P
Wellcome Open Res. 2019; 4:56.
PMID: 31346551
PMC: 6619368.
DOI: 10.12688/wellcomeopenres.15147.2.
Time trends in oral bisphosphonate initiation in Ontario, Canada over 20 years reflect drug policy and healthcare delivery changes.
Hayes K, Ban J, Athanasiadis G, Burden A, Cadarette S
Osteoporos Int. 2019; 30(11):2311-2319.
PMID: 31317249
DOI: 10.1007/s00198-019-05061-z.
Both non-surgical dental treatment and extractions increase the risk of medication-related osteonecrosis of the jaw: case-control study.
McGowan K, Ware R, Acton C, Ivanovski S, Johnson N
Clin Oral Investig. 2019; 23(11):3967-3975.
PMID: 30747305
DOI: 10.1007/s00784-019-02828-w.
Adverse effects of media reports on the treatment of osteoporosis.
Cipriani C, Pepe J, Minisola S, Lewiecki E
J Endocrinol Invest. 2018; 41(12):1359-1364.
PMID: 29761280
DOI: 10.1007/s40618-018-0898-9.
Hip fracture trends in the United States, 2002 to 2015.
Lewiecki E, Wright N, Curtis J, Siris E, Gagel R, Saag K
Osteoporos Int. 2017; 29(3):717-722.
PMID: 29282482
DOI: 10.1007/s00198-017-4345-0.
Barriers to Effective Postmenopausal Osteoporosis Treatment: A Qualitative Study of Patients' and Practitioners' Views.
Alami S, Hervouet L, Poiraudeau S, Briot K, Roux C
PLoS One. 2016; 11(6):e0158365.
PMID: 27355576
PMC: 4927112.
DOI: 10.1371/journal.pone.0158365.
The effect of two doses of dried plum on bone density and bone biomarkers in osteopenic postmenopausal women: a randomized, controlled trial.
Hooshmand S, Kern M, Metti D, Shamloufard P, Chai S, Johnson S
Osteoporos Int. 2016; 27(7):2271-2279.
PMID: 26902092
DOI: 10.1007/s00198-016-3524-8.
Impact of a change in physician reimbursement on bone mineral density testing in Ontario, Canada: a population-based study.
Jaglal S, Hawker G, Croxford R, Cameron C, Schott A, Munce S
CMAJ Open. 2014; 2(2):E45-50.
PMID: 25077129
PMC: 4084743.
DOI: 10.9778/cmajo.2013-0052.
Bisphosphonate-related osteonecrosis of the jaw in non-malignant bone disease.
Wong P, Borromeo G, Wark J
Rheumatol Int. 2013; 33(9):2189-98.
PMID: 23652790
DOI: 10.1007/s00296-013-2771-7.
Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) project.
Edwards B, Bunta A, Lane J, Odvina C, Rao D, Raisch D
J Bone Joint Surg Am. 2013; 95(4):297-307.
PMID: 23426763
PMC: 3748968.
DOI: 10.2106/JBJS.K.01181.
The role of risk communication in the care of osteoporosis.
Lewiecki E
Curr Osteoporos Rep. 2011; 9(3):141-8.
PMID: 21505788
DOI: 10.1007/s11914-011-0056-1.
Safety of long-term bisphosphonate therapy for the management of osteoporosis.
Lewiecki E
Drugs. 2011; 71(6):791-814.
PMID: 21504254
DOI: 10.2165/11585470-000000000-00000.
Bisphosphonate use and hip fracture epidemiology: ecologic proof from the contrary.
Fisher A, Martin J, Srikusalanukul W, Davis M
Clin Interv Aging. 2011; 5:355-62.
PMID: 21228901
PMC: 3010171.
DOI: 10.2147/CIA.S13909.